ACB
Aurora Cannabis Inc.
ACB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ACB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ACB's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ACB PE Valuation
ACB has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Improving | |
| Limited | |
| High |
ACB has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.36 | -500% |
| Q1 2026 | -$0.91 | -2375% |
| Q4 2025 | -$0.53 | -431% |
| Q3 2025 | -$0.14 | +$0.47 |
| Q2 2025 | $0.34 | +$0.80 |
| Q1 2025 | $0.04 | +$1.18 |
| Q4 2024 | $0.16 | +$2.37 |
| Q3 2024 | -$0.61 | +$2.63 |
ACB has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $47.5M | -23% |
| Q1 2026 | $26.8M | -58% |
| Q4 2025 | $66.2M | +6.8% |
| Q3 2025 | $63.5M | +11% |
| Q2 2025 | $62M | +5.7% |
| Q1 2025 | $63.7M | +34% |
| Q4 2024 | $62M | +37% |
| Q3 2024 | $57M | +29% |
ACB's revenue is shrinking: $48M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -70% | -112 points |
| Q1 2026 | -66% | -33 points |
| Q4 2025 | 5.1% | -37 points |
| Q3 2025 | -20% | -17 points |
| Q2 2025 | 42% | +41 points |
| Q1 2025 | -34% | -38 points |
| Q4 2024 | 42% | +69 points |
| Q3 2024 | -3% | +14 points |
ACB's operating margin was −70% last quarter, down 112 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ACB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ACB on profitability, with a higher operating margin.
ACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -294% |
| Q1 2026 | -$3.8M | -$3.4M |
| Q4 2025 | $7.7M | -54% |
| Q3 2025 | -$32.9M | -$12.2M |
| Q2 2025 | $3.6M | +58% |
| Q1 2025 | -$438K | +$18.4M |
| Q4 2024 | $16.9M | +$22.5M |
| Q3 2024 | -$20.7M | +$4M |
ACB has burned cash in most quarters: −$36M over the past year, against −$702,335 the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ACB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +4.2M shares |
| 1 year | +11% | +5.9M shares |
| 3 years | +74% | +26.3M shares |
| 5 years | +212% | +41.9M shares |
| Available history | +612% | +53M shares |
ACB has 62M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ACB hasn't bought back shares in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ACB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ACB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -4.5x | Net Cash |
| Q2 2024 | -5.2x | Net Cash |
| Q4 2023 | -0.2x | Net Cash |
ACB has the edge over HIMS on leverage, with a lower net debt burden relative to earnings.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 84.8 | Overbought |
ACB's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ACB PE vs Healthcare Sector
| Metric | ACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACB has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.33 | 15% above |
| 20 week MA | $3.72 | 34% above |
| 50 week MA | $3.73 | 34% above |
| 100 week MA | $4.26 | 17% above |
| 200 week MA | $5.00 | 0.2% below |
ACB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $229.2 | $88.7 | -61% |
| 2021 | $88.7 | $61.2 | -31% |
| 2022 | $61.2 | $9.27 | -85% |
| 2023 | $9.27 | $4.76 | -49% |
| 2024 | $4.76 | $4.30 | -9.7% |
| 2025 | $4.30 | $4.49 | +4.4% |
| 2026 YTD | $4.49 | $4.99 | +11% |
ACB has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.